The South & Central America organoids market is expected to grow from US$ 132.38 million in 2022 to US$ 654.25 million by 2030. It is estimated to grow at a CAGR of 22.1% from 2022 to 2030.
Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ's original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study ‘CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,’ published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids' safety, long-term stability, and functionality.
Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.
Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the South & Central America organoids market in 2022.
Based on type, the South & Central America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the South & Central America organoids market in 2022.
Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held the larger share of the South & Central America organoids market in 2022.
Based on country, the South & Central America organoids market is segmented into the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America organoids market in 2022.
Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, are some of the leading companies operating in the South & Central America organoids market.
Focus on Drug Discovery Activities Fuel South & Central America Organoids Market
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ's original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study ‘CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,’ published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids' safety, long-term stability, and functionality.
Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.
South & Central America Organoids Market Overview
The South & Central America organoids market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the increasing number of cancer cases, growing government initiatives, and rising research and development for organoids.South & Central America Organoids Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Organoids Market Segmentation
The South & Central America organoids market is segmented into organ type, type, application, Source, and country.Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the South & Central America organoids market in 2022.
Based on type, the South & Central America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the South & Central America organoids market in 2022.
Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held the larger share of the South & Central America organoids market in 2022.
Based on country, the South & Central America organoids market is segmented into the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America organoids market in 2022.
Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, are some of the leading companies operating in the South & Central America organoids market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. South & Central America Organoids Market Landscape
5. South & Central America Organoids Market - Key Industry Dynamics
6. Organoids Market - South & Central America Market Analysis
7. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Organ Type.
8. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Application.
9. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Source.
10. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Type
11. South & Central America Organoids Market - Country Analysis
12. Pre & Post COVID-19 Impact
13. South & Central America Organoids Market Industry Landscape
14. South & Central America Organoids Market, Key Company Profiles
15. Appendix
List of Tables
List of Figures
Executive Summary
At 22.1% CAGR, the South & Central America Organoids Market is speculated to be worth US$ 654.25 million by 2030.According to this research, the South & Central America Organoids market was valued at US$ 132.38 million in 2022 and is expected to reach US$ 654.25 million by 2030, registering a CAGR of 22.1% from 2022 to 2030. Combining organoid with organ-on-a-chip is the critical factor attributed to the South & Central America Organoids market expansion.
Organoid and organ-on-a-chip, which serve as evolving pathological and human physiological relevant in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits. The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. By incorporating multiple organoids into organ-on-a-chip, organoid-on-a-chip can inherit benefits of both organoid and organ-on-a-chip and provide a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions.
In addition, technological advancements will facilitate various applications in biological and biomedical fields for disease modeling and clinical drug screening by combining organoids with organ-on-a-chip. Technological advancements have enabled the development of brain organoids-on-chip, liver organoids-on-chip, intestine organoids-on-chip, and more. Although organoid-on-a-chip is currently a developing field, much scope exists for improvement. Thus, it will also require cooperative efforts from interdisciplinary researchers to reach organoids' full utility in human biomedical studies and lead the market’s growth in the coming future.
On the contrary, issues related to incorporation of organoids into existing workflows and dearth of skilled professionals hampers the South & Central America organoids market.
Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.0% share of South & Central America organoids market in 2022, amassing US$ 30.49 million. It is projected to garner US$ 147.92 million by 2030 to expand at 21.8% CAGR during 2022-2030.
Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.7% share of South & Central America organoids market in 2022, amassing US$ 39.36 million. It is projected to garner US$ 203.58 million by 2030 to expand at 22.8% CAGR during 2022-2030.
Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 71.9% share of South & Central America organoids market in 2022, amassing US$ 95.16 million. It is projected to garner US$ 485.25 million by 2030 to expand at 22.6% CAGR during 2022-2030.
Based on type, the South & Central America organoids market is segmented into instruments, consumables, and services. The consumables segment held 61.0% share of South & Central America organoids market in 2022, amassing US$ 80.78 million. It is projected to garner US$ 419.35 million by 2030 to expand at 22.9% CAGR during 2022-2030.
Based on country, the South & Central America organoids market has been categorized into the Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 65.9% share of South & Central America organoids market in 2022. It was assessed at US$ 87.29 million in 2023 and is likely to hit US$ 439.53 million by 2030, exhibiting a CAGR of 22.4% during 2022-2030.
Key players operating in the South & Central America organoids market are Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.
In Feb 2023, the collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cellesce
- InSphero
- Merck KGaA
- STEMCELL Technologies Inc
- Thermo Fisher Scientific Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 82 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value in 2022 | 132.38 Million |
| Forecasted Market Value by 2030 | 654.25 Million |
| Compound Annual Growth Rate | 22.1% |
